Retlirafusp Alfa

Phase 2

TTang-Du Hospital

Retlirafusp Alfa is one of 141 therapeutic programs targeting Colorectal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

140

Competitors

Pipeline

Status by Indication[2][1]

Indication

Colorectal CarcinomaNot yet recruiting

Esophageal CancerNot yet recruiting

Gastric AdenocarcinomaNot yet recruiting

Pancreatic CancerNot yet recruiting

Gastric Cancer (GC)Active, not recruiting

Triple Negative Breast Cancer (TNBC)Not yet recruiting

Gastric Cancer (diagnosis)Not yet recruiting

Colorectal CarcinomaPhase 2

Not yet recruiting

Esophageal CancerPhase 2

Not yet recruiting

Gastric AdenocarcinomaPhase 2

Not yet recruiting

Pancreatic CancerPhase 2

Not yet recruiting

Gastric Cancer (GC)Preclinical

Active, not recruiting

Triple Negative Breast Cancer (TNBC)Phase 2

Not yet recruiting

Gastric Cancer (diagnosis)Phase 2

Not yet recruiting

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Retlirafusp Alfa

TTang-Du Hospital

Phase 2

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 6

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 7

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

1 10

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalActive, not recruiting

Gastric Cancer (GC)

NCT07855757

Q4 2028

Phase 2Not yet recruiting

Gastric Cancer/gastroesophageal Junction Adenocarcinoma

NCT07874425

PreclinicalRecruiting

Hepatocellular

NCT06893887

Phase 2Not yet recruiting

Pancreatic Cancer

NCT07773363

Q1 2029

Phase 2Recruiting

Intrahepatic Cholangiocarcinoma (icc)

NCT07847710

Phase 2Not yet recruiting

Esophageal Cancer

NCT07770672

Clinical

Trials by Indication[1]

Gastric Cancer (Diagnosis)1 trial

Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis

Not yet recruiting·AAnhui Provincial Cancer Hospital·Phase 2·NCT07904442·32 enrolled

Intrahepatic Cholangiocarcinoma (Icc)1 trial

Perioperative Retlirafusp Alfa（Anti-PD-L1/TGF-β Bifunctional Fusion Protein） Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II Trial: H-FROG Feasibility Study

Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07847710·81 enrolled

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma1 trial

An Exploratory Clinical Study of Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·FFudan University·Phase 2·NCT07874425·55 enrolled

Gastric Cancer (GC)1 trial

An Exploratory Study of Retlirafusp Alfa in Combination With SOX and Intraperitoneal Nab-Paclitaxel as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma With Malignant Ascites

Active, not recruiting·ZZhejiang Cancer Hospital·Preclinical·NCT07855757·5 enrolled

Hepatocellular1 trial

Exploratory Cohort Study and Mechanistic Research on Individualized Comprehensive Treatment After Standard Treatment for Advanced Hepatocellular Carcinoma

Recruiting·NNanjing Tianyinshan Hospital·Preclinical·NCT06893887·270 enrolled

5 more indications

Colorectal Carcinoma1 trial

A Single-Arm, Phase II Study of Retlirafusp Alfa in Combination With XELOX and Bevacizumab for the First-Line Treatment of Advanced RAS-Mutated Colorectal Cancer With Liver Metastases (CRLM)

Not yet recruiting·DDai, Guanghai·Phase 2·NCT07797244·46 enrolled

Pancreatic Cancer1 trial

A Prospective, Open-Label, Single-Arm Clinical Study of Retlirafusp Alfa Combined With Apatinib and Chemotherapy as Second-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT07773363·37 enrolled

Esophageal Cancer1 trial

An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging

Not yet recruiting·TTan Lijie·Phase 2·NCT07770672·92 enrolled

Triple Negative Breast Cancer (TNBC)1 trial

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer: An Exploratory Clinical Study

Not yet recruiting·HHarbin Medical University·Phase 2·NCT07752550·120 enrolled

Gastric Adenocarcinoma1 trial

A Single-Arm, Exploratory Study of Retlirafusp Alfa Plus Chemotherapy as Conversion Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·TTang-Du Hospital·Phase 2·NCT07709767·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Retlirafusp Alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Retlirafusp Alfa. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Tang-Du Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: TTang-Du Hospital

Retlirafusp Alfa

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Q1 2029

Trials by Indication[1]

Gastric Cancer (Diagnosis)1 trial

Intrahepatic Cholangiocarcinoma (Icc)1 trial

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma1 trial

Gastric Cancer (GC)1 trial

Hepatocellular1 trial

Colorectal Carcinoma1 trial

Pancreatic Cancer1 trial

Esophageal Cancer1 trial

Triple Negative Breast Cancer (TNBC)1 trial

Gastric Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News